-
Something wrong with this record ?
The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. Case-control study and meta-analysis
M. Rehak, J. Rehak, M. Müller, S. Faude, F. Faude, A. Siegemund, V. Krcova, L. Slavik, D. Hasenclever, M. Scholz, P. Wiedemann,
Language English Country Germany
Document type Journal Article, Meta-Analysis, Multicenter Study
PubMed
18449423
DOI
10.1160/th07-11-0658
Knihovny.cz E-resources
- MeSH
- Adult MeSH
- Factor V genetics MeSH
- Genetic Predisposition to Disease MeSH
- Genetic Testing MeSH
- Risk Assessment MeSH
- Middle Aged MeSH
- Humans MeSH
- Odds Ratio MeSH
- Retinal Vein Occlusion epidemiology etiology genetics MeSH
- Prevalence MeSH
- Activated Protein C Resistance complications epidemiology genetics MeSH
- Risk Factors MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Case-Control Studies MeSH
- Thromboembolism complications MeSH
- Age Factors MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Meta-Analysis MeSH
- Multicenter Study MeSH
- Geographicals
- Czech Republic MeSH
- Germany MeSH
Several small case-control studies have investigated whether factor V Leiden (FVL) is a risk factor for retinal vein occlusion (RVO) and generated conflicting data. To clarify this question we performed a large two-centre case-control study and a meta-analysis of published studies. Two hundred seven consecutive patients with RVO and a control group of 150 subjects were screened between 1996 and 2006. A systematic meta-analysis was done combining our study with further 17 published European case-control studies. APC resistance was detected in 16 out of 207 (7.7%) patients and eight out of 150 (5.3%) controls. The odds ratio (OR) estimated was 1.49 with a (non-significant) 95% confidence interval (CI) of 0.62-3.57. The meta-analysis including 18 studies with a total of 1,748 patients and 2,716 controls showed a significantly higher prevalence of FVL in patients with RVO compared to healthy controls (combined OR 1.66; 95% CI 1.19-2.32). All single studies combined in the meta-analysis were too small to reliably detect the effect individually. This explains the seemingly contradictory data in the literature. In conclusion, the prevalence of APC resistance (and FVL) is increased in patients with RVO compared to controls, but the effect is only moderate. Therefore, there is no indication for general screening of factor V mutation in all patients with RVO. We recommend this test to be performed in patients older than 50 years with an additional history of thromboembolic event and in younger patients without general risk factors like hypertension.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20014399
- 003
- CZ-PrNML
- 005
- 20200921152842.0
- 007
- ta
- 008
- 200918s2008 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1160/TH07-11-0658 $2 doi
- 035 __
- $a (PubMed)18449423
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Rehak, Matus $u Department of Ophthalmology, University Hospital Leipzig, Liebigstrasse 10-14, 04103 Leipzig, Germany.
- 245 14
- $a The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. Case-control study and meta-analysis / $c M. Rehak, J. Rehak, M. Müller, S. Faude, F. Faude, A. Siegemund, V. Krcova, L. Slavik, D. Hasenclever, M. Scholz, P. Wiedemann,
- 520 9_
- $a Several small case-control studies have investigated whether factor V Leiden (FVL) is a risk factor for retinal vein occlusion (RVO) and generated conflicting data. To clarify this question we performed a large two-centre case-control study and a meta-analysis of published studies. Two hundred seven consecutive patients with RVO and a control group of 150 subjects were screened between 1996 and 2006. A systematic meta-analysis was done combining our study with further 17 published European case-control studies. APC resistance was detected in 16 out of 207 (7.7%) patients and eight out of 150 (5.3%) controls. The odds ratio (OR) estimated was 1.49 with a (non-significant) 95% confidence interval (CI) of 0.62-3.57. The meta-analysis including 18 studies with a total of 1,748 patients and 2,716 controls showed a significantly higher prevalence of FVL in patients with RVO compared to healthy controls (combined OR 1.66; 95% CI 1.19-2.32). All single studies combined in the meta-analysis were too small to reliably detect the effect individually. This explains the seemingly contradictory data in the literature. In conclusion, the prevalence of APC resistance (and FVL) is increased in patients with RVO compared to controls, but the effect is only moderate. Therefore, there is no indication for general screening of factor V mutation in all patients with RVO. We recommend this test to be performed in patients older than 50 years with an additional history of thromboembolic event and in younger patients without general risk factors like hypertension.
- 650 _2
- $a rezistence k aktivovanému proteinu C $x komplikace $x epidemiologie $x genetika $7 D020016
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a věkové faktory $7 D000367
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a studie případů a kontrol $7 D016022
- 650 _2
- $a faktor V $x genetika $7 D005165
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a genetická predispozice k nemoci $7 D020022
- 650 _2
- $a genetické testování $7 D005820
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a odds ratio $7 D016017
- 650 _2
- $a prevalence $7 D015995
- 650 _2
- $a okluze retinální žíly $x epidemiologie $x etiologie $x genetika $7 D012170
- 650 _2
- $a hodnocení rizik $7 D018570
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a tromboembolie $x komplikace $7 D013923
- 651 _2
- $a Česká republika $7 D018153
- 651 _2
- $a Německo $7 D005858
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a metaanalýza $7 D017418
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Rehak, Jiri
- 700 1_
- $a Müller, Marc
- 700 1_
- $a Faude, Susanne
- 700 1_
- $a Faude, Frank
- 700 1_
- $a Siegemund, Annelie
- 700 1_
- $a Krcova, Vera
- 700 1_
- $a Slavik, Ludek
- 700 1_
- $a Hasenclever, Dirk
- 700 1_
- $a Scholz, Markus
- 700 1_
- $a Wiedemann, Peter
- 773 0_
- $w MED00004517 $t Thrombosis and haemostasis $x 0340-6245 $g Roč. 99, č. 5 (2008), s. 925-929
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/18449423 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200918 $b ABA008
- 991 __
- $a 20200921152841 $b ABA008
- 999 __
- $a ok $b bmc $g 1565251 $s 1104557
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2008 $b 99 $c 5 $d 925-929 $e - $i 0340-6245 $m Thrombosis and haemostasis $n Thromb Haemost $x MED00004517
- LZP __
- $a Pubmed-20200918